Larimar Therapeutics Reports $47.7 Million Net Loss in Q3 2025, Driven by Increased R&D Expenses

Larimar Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $47.7 million for the third quarter, compared to a loss of $15.5 million in the same period last year, marking a 208% increase in losses. For the nine months ended September 30, 2025, the net loss totaled $103.2 million, up from $51.8 million in the prior year. The increase in losses is primarily attributed to a substantial rise in research and development expenses, which surged to $44.9 million for the quarter, up from $13.9 million in the previous year, driven largely by increased manufacturing costs for its lead product candidate, nomlabofusp.

The company's total operating expenses for the third quarter reached $49.5 million, a significant increase from $18.3 million in the same quarter of 2024. This rise reflects heightened activity in clinical studies and regulatory efforts associated with nomlabofusp, which is being developed for the treatment of Friedreich's ataxia. The company also reported a total cash position of approximately $90.1 million in cash and cash equivalents as of September 30, 2025, a notable increase from $33.2 million at the end of 2024, bolstered by a public offering that raised approximately $65 million in July 2025.

In terms of operational metrics, Larimar has made strides in its clinical development program. The company has completed four clinical studies for nomlabofusp, including two Phase 1 studies and a Phase 2 dose exploration study. As of September 2025, 65 participants have received at least one dose of nomlabofusp, with ongoing studies showing consistent improvements in clinical outcomes and FXN levels, a key protein targeted by the therapy. The company has also amended its open-label study protocol to include a broader patient population, which is expected to enhance the robustness of its clinical data.

Looking ahead, Larimar plans to submit a Biologics License Application (BLA) seeking accelerated approval for nomlabofusp in the second quarter of 2026. The company is actively preparing for a global Phase 3 study and continues to engage with regulatory agencies, including the FDA and EMA, to facilitate the development of its product candidate. Despite the current financial losses, Larimar's management remains optimistic about the potential for nomlabofusp to address unmet medical needs in rare diseases, while also acknowledging the ongoing need for additional capital to support its operations and clinical development efforts.